BeiGene, Ltd.
IMMUNOMONOTHERAPY FOR UROTHELIAL CARCINOMA
Last updated:
Abstract:
Disclosed herein is a method for immunotherapy of a patient with urothelial carcinoma (UC) comprising administering to the patient an anti-PD-1 antibody reduces Fc.gamma.R binding thus reducing antibody-dependent phagocytosis.
Status:
Application
Type:
Utility
Filling date:
8 Feb 2019
Issue date:
11 Feb 2021